PubMed Health⌕ Search

PubMed · 10939170

[The brain, movement and space].

Abstract

The combination, in humans, of methods of experimental Psychology, of brain imagery by position tomography, and functional MRI, and in animals of fine methods of neuronal recordings, has allowed us to reveal the neural mechanisms of the control of gaze. Thus is now available as important knowledge which can be used in Neuro-Ophthalmology for the understanding of the deficits of gaze control and in Neuro-Otology for the understanding of the vestibular disorders. We have also explored the neural basis of spatial memory and spatial disorientation such as observed in psychiatric symptoms as agoraphobia. Here again through a combination of neuronal recordings in the rat, brain imagery in normal human and studies with neurological patients, we have discovered some of the mechanisms which are involved in the memory of space during navigation tasks. In particular we have shown the role of the limbic system and of parieto-frontal systems in this processes. These results open new avenues in Neurology for the understanding of symptoms such as spatial neglect or topographic memory or perturbation in the control of posture and locomotion.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Berthoz. 1999. [The brain, movement and space].. https://pubmed.ncbi.nlm.nih.gov/10939170/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Are there gender differences in catastrophic appraisals in panic disorder with agoraphobia?

Our aim in this study was to compare panic-related catastrophic appraisals between women and men with panic disorder with agoraphobia (PDA). One hundred two outpatients with PDA (75 women and 27 men) participated. Two instruments for the assessment of catastrophic appraisals, Agoraphobic Cognitions Questionnaire and Panic Appraisal Inventory, were administered before and after cognitive-behavioral therapy (CBT) that also included pharmacotherapy in three-fourths of the patients. Female and male patients did not differ significantly in terms of their tendency to anticipate catastrophic consequences of panic, before or after CBT-based treatment. For both females and males, the tendency to make catastrophic appraisals decreased significantly with treatment. We conclude that among patients with PDA there are no gender differences in catastrophic appraisals of panic sensations and symptoms. The apparently higher risk of panic recurrence in women does not seem to be related to their panic-related catastrophic appraisals. These findings also support a notion that there is no gender difference in response to CBT-based treatment of PDA.

Agoraphobia↗

Panic and avoidance in panic disorder with agoraphobia: clinical relevance of change in different aspects of the disorder.

Different aspects of change were examined in 62 patients who fulfilled the DSM-IV criteria for a primary diagnosis of panic disorder with agoraphobia of moderate to severe magnitude, and who were treated with 16 sessions of behavioral therapy. The treatment resulted in substantial effects on panic attacks and agoraphobic avoidance. Panic-free status only differentiated the patients regarding mood at pre- and post-treatment. Changes in panic and avoidance were related to each other, but change in avoidance was more related to change in negative affect. Change in quality of life (QOL) was also more associated with change in avoidance at post-treatment. At follow-up change in QOL was more related to change in panic than change in avoidance.

Agoraphobia↗

Pregabalin: From molecule to medicine.

Pregabalin, a compound with a novel mechanism of action (MOA), has demonstrated efficacy as an adjunctive treatment for epilepsy and in several neuropathic pain models. Multiple generalized anxiety disorder (GAD) clinical trials have shown that pregabalin has efficacy similar to the benzodiazepines and venlafaxine. Onset of anxiolytic effect was observed as early as Week 1 of treatment, and efficacy was seen in treating both psychic and somatic anxiety symptoms. Pregabalin binds potently and selectively to the alpha-2-delta subunit of "hyper-excited" voltage-gated calcium channels (VGCCs). The binding of pregabalin to VGCCs changes their conformation, reducing calcium influx at nerve terminals. Pregabalin only modulates the release of excitatory neurotransmitters in "hyper-excited" neurons, restoring them to normal physiological state. This newly defined MOA is believed to confer on pregabalin its anxiolytic, analgesic, and anticonvulsant properties. Thus, pregabalin may offer physicians an effective and well-tolerated therapy for GAD, which differs from existing treatments.

Agoraphobia↗